Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19 clinical trials
Also written CNCT19.
How each study uses Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 6
Institute of Hematology & Blood Diseases Hospital, China (2) · Peking Union Medical College Hospital (1) · First Affiliated Hospital of Zhejiang University (1) · Ruijin Hospital (1) · Juventas Cell Therapy Ltd. (1) · Shandong University (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19.
- Dec 2026Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1Phase 2 · First Affiliated Hospital of Zhejiang University
- Jun 2027A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune DiseasesEarly Phase 1 · Juventas Cell Therapy Ltd.
Studies
Open first, then newest update. How each study uses Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1RecruitingPhase 2Ruijin HospitalNCT06718244Written as single dose of Inaticabtagene autoleucel
- A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune DiseasesRecruitingEarly Phase 1Juventas Cell Therapy Ltd.NCT07275736Written as CNCT19 cell injection
- Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1Not yet recruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06777264Written as Biological: single dose of Inaticabtagene autoleucel
- CNCT19 Cell Injection for Refractory Systemic Lupus ErythematosusEnrolling by invitationEarly Phase 1Peking Union Medical College HospitalNCT05930314Written as CNCT19 cell injection
- CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.Active, not recruitingPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT06231368Written as CNCT19 CAR-T cell therapy
- CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell LymphomaCompletedPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT04690192Written as CNCT19
- A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell MalignanciesStatus unknownEarly Phase 1Shandong UniversityNCT04011293Written as CNCT19